Signed in as:
filler@godaddy.com
Antibiotic Resistance (ABR-1) Panel
Antimicrobial Resistance Genes
- KPC
- VIM
- IMP
- QNR
- OXA
- mecA/C
- Van A / Van B
- Sul1-2
- Ctx
- DfrA
Respiratory Pathogen Panel (Mini-RPP)
Our Mini-RPP uses FDA EUA-authorized RT-PCR technology to rapidly detect key respiratory pathogens with high sensitivity and specificity. Designed for streamlined diagnostics, this panel helps clinicians quickly differentiate between viral and bacterial infections to guide appropriate treatment and infection control. With a focused target set, it supports timely care in both outpatient and long-term care settings - without the delays of broad respiratory panels.
- SARS-CoV-2
- Influenza A
- Influenza B
- Respiratory Syncytial Virus A/B (RSV A/B)
- H5N1
Sexually Transmitted Infection (STI) Panel
Our comprehensive STI panel detects a wide range of bacterial, viral, and protozoal pathogens with high accuracy using RT-PCR. This molecular-based approach enables early and reliable detection of infections such as Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Herpes Simplex Virus (HSV), and others. With rapid results and broad coverage, this panel supports timely diagnosis, treatment, and partner management in both acute and asymptomatic cases.
Fungal Infection Panel
Our fungal panel provides precise detection of pathogenic fungi, including yeast species and dermatophytes associated with superficial and systemic infections. Utilizing RT-PCR for rapid and accurate identification, the panel targets clinically significant organisms. Early molecular diagnosis supports targeted antifungal treatment, minimizes diagnostic delays, and improves patient outcomes - especially in immunocompromised or high-risk populations.
Pharmacogenomics (PGx) Panel
Our comprehensive Pharmacogenomics (PGx) panel provides actionable genetic insights to guide precise medication selection, dosing, and safety monitoring. By analyzing key CYP450 enzymes, drug-metabolism pathways, and genetic variants linked to efficacy and adverse drug responses, clinicians can optimize therapy for pain management, behavioral health, cardiology, primary care, and high-risk polypharmacy populations.
This panel supports personalized medicine, reduces trial-and-error prescribing, and helps prevent drug toxicity, treatment failure, and avoidable readmissions. Results integrate seamlessly into clinical workflows to enhance outcomes, patient safety, and therapeutic effectiveness.
